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Abstract
Background. Canine hepatocellular adenomas are benign, well-differentiated, primary hepatic tumors. Surgical resection is
technically demanding and is considered a major procedure with relatively high morbidity rates. Magnetic resonance-guided
focused ultrasound surgery (MRgFUS) uses focused ultrasonic energy to non-invasively create a heat-coagulated lesion
deep within the body. This effect can be achieved in a controlled, accurate manner. The aim of this study was to evaluate the
safety, accuracy and efficacy of non-invasive focal ablation of tissue volumes of a canine benign liver tumour by consecutive
MRgFUS sonications. Materials and methods. Four MRgFUS procedures were performed in a 10-year-old, male, mixed
large breed dog (45 kg) under general anaesthesia. The exact location and volume of the ablated areas were planned on the
MR images. Real-time MR imaging and temperature mapping enabled the immediate evaluation of the effect of each
sonication. Different areas were chosen within the tumour. These volumes of tumoral tissue were ablated by multiple
sonications. To allow accurate targeting and quality imaging, sonications were performed during 2030 s of apnoea.
Between the sonications the dog was normally ventilated. The dog was operated 21 days after the fourth ablative procedure.
The tumour was resected and histopathologically examined. Results. The MRgFUS created necrosis with contiguous areas
of complete tissue destruction within the liver tumour, in full accordance with the planning. A focal thermal injury to the
cartilage of the right lower ribs was noted after the fourth treatment. This lesion became infected and was treated surgically.
Ten months after the last treatment the dog is well and healthy. Conclusions. Focused ultrasound ablation of liver tumoral
tissue with MR guidance under general anaesthesia and controlled apnoea is a safe and accurate treatment modality. Its
main advantage is that it is a completely non-invasive image-guided treatment. The ablation of significant volumes of a
highly vascular liver tumoral tissue was achieved. Such tissue can be ablated in a very accurate manner, exactly according to
the pretreatment planning on the MR images. The MR imaging characteristics, including real-time temperature mapping,
enable real-time control of every step of the ablation process. Mechanical ventilation with intermittent apnoea periods
overcomes the problem of the respiratory movements of the liver. Care must be taken to avoid the passage of the ultrasound
beam through energy-absorbing calcified tissue.
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Introduction
Canine hepatocellular adenomas are benign, well-
differentiated, primary hepatic tumours, most often
diagnosed as an incidental finding. These tumours
occur with a higher frequency than the malignant
counterpart, and usually occur in dogs over 10 years
of age. Grossly, adenomas appear well circumscribed
and demarcated. They are usually single, may be quite
large (up to 20 cm) and often exhibit a pedunculated
attachment. Adenomas consist of a friable, highly
vascular parenchyma, and rupture with subsequent
haemoperitoneum may be the clinical presentation.
Grossly and histologically, these tumours may be
difficult to distinguish from nodular hyperplasia or
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even normal liver tissue. Histologically, encapsulation
and compression of adjacent hepatic parenchyma are
characteristic features. Complete surgical resection is
curative but by the time of diagnosis high tumour
burden may make this unachievable. The prognosis for
respectable hepatocellular adenomas is good, and
survival times of up to 2 years have been reported [1,2].
Liver tumours are among the most common
tumours in human beings. Surgical removal is very
often the only chance for cure, but only a small
percentage is operable. Major liver surgery is techni-
cally a demanding and complicated procedure with
high morbidity rates [3]. In the last few decades, liver
surgery has changed dramatically, to a well under-
stood, accurate, anatomical procedure with accepta-
ble low rates of complications [4]. Minimally invasive
ablative technologies such as ethanol injection, micro-
wave, laser ablation, radiofrequency and cryoablation
are being used primarily for non-resectable liver
tumours, or as adjuvant palliative procedures. These
technologies suffer the lack of real-time control of
their efficacy [511]. The ablation of primary liver
tumours by a non-real-time control, ultrasound-
guided focused ultrasound has been reported recently
[12]. The integration of focused ultrasound and
magnetic resonance imaging resulted in a new pro-
minent method of non-invasive surgery. By using this
integrated delivery system, the surgeon can correctly
localize tumours, optimally deliver acoustic energy
(‘sonicate’), monitor energy deposition in real time,
and accurately control the deposited thermal dose
within the entire volume of the tumour. This novel
technology represents a potential useful treatment
modality in liver surgery [13], and also in other
surgical fields [13,14]. However, to deliver safe and
effective treatment to the liver with magnetic
resonance-guided focused ultrasound surgery
(MRgFUS), the clinician has to overcome the pro-
blem of respiratory movement of the liver during
energy delivery. Otherwise, the energy might not be
delivered to the planned focused region, the energy
might become unfocused, and the magnetic reso-
nance (MR) system may be unable to provide quality
thermal imaging.
This study aimed to evaluate the safety and
accuracy of MRgFUS for the focal ablation of tumoral
tissue within the liver, in a totally non-invasive
manner, using general anaesthesia with intermittent
short periods of apnoea.
Materials and methods
A 10-year-old, male, mixed large breed dog (45 kg)
had been diagnosed at the Koret School of Veterinary
Medicine Hospital to have a huge, asymptomatic,
irresectable hepatocellular adenoma (Figure 1). Four
separate MRgFUS procedures were performed during
a period of 8 weeks, under general anaesthesia. The
induction and maintenance were achieved by: i.v.
fentanil 0.002 mg/kg/h, i.v. propofol 2 mg/kg/h and i.v.
atracurium 0.5 mg/kg/h. The dog was intubated and
kept under controlled, positive pressure, mechanical
ventilation using an operating room portable ventila-
tor (Ivent 201 v. 1.4, VersaMed Inc., Pearl River, NY
10965, USA), delivering a respiratory rate of 14/min,
FiO2 of 0.4, and PEEP of 7 cmH2O. The ablation of
each area within the tumour was created by the
combined ablative focused thermal effect of several
sonications. Sonications were performed with the
MRgFUS system, using a phased array transducer
of 208 elements (ExAblate 2000, InSightec, Tirat
Hacarmel, Israel) and MR, Signa Twinspeed 1.5T
(GEHC, USA).
Areas within the huge tumour were defined as
targets for ablation by the MRgFUS. These were
outlined on the planning screen of a single coronal
view of the MR image. In all the four treatments of
this tumour, the treated volume was planned to create
only one layer of adjacent sonications. The ablation
planning software (ExAblate 2000, Version 4.1
InSightec) calculated the type and number of sonica-
tions required to completely destroy the defined
region within the tumour. During each sonication,
the energy of an ultrasound beam was focused at a
small bean-shaped volume of tissue and was directed
into the target for 512 s, heating the tissue to induce
thermal coagulation. Each sonication was controlled
in real time by the MR scanning and thermometry for
anatomical accuracy and thermal efficiency. Once
sonication was completed at one point, the transducer
was automatically moved to the next treatment point
and the process was repeated until the entire target
tissue had been ablated. These MR images, taken
during sonication, provided a diagnostic quality image
of the target tissue and a quantitative, real-time
temperature map overlay to confirm the therapeutic
effect of the treatment.
The tumour areas chosen as targets for ablation
varied in volume and were located in different aspects
Figure 1. An axial CT image of the huge hepatocellular adenoma.
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of the tumour. These predefined areas within the
tumour were each ablated by multiple sonications.
The ablative focus of each sonication is jellybean-
shaped and its dimensions can be controlled. In each
treatment session we applied foci of different mea-
surements: 0.320.64 cm in diameter and 2.23.4
cm in length. There was a 25% overlap between
adjacent sonications. Each sonication was performed
during apnoea. Apnoea periods always started at the
end of inspirium and ranged from 22 to 30 s. Between
phases of apnoea, controlled mechanical ventilation
(CMV) periods of 90 s were applied. The dog was
monitored continuously to evaluate its haemodynamic
status and blood oxygen saturation. Arterial blood
levels of gases, pH, electrolytes and blood counts were
taken periodically during the procedure. At the end of
the ablative procedures, MR scans including axial,
sagittal, and coronal views with i.v. contrast agent 2.5
ml/kg (Dotarem, Guerbet, 95943 Roissy CdG cedex,
France) were performed to evaluate the location,
shape and volume of the ablated, non-perfused areas.
We used sonications of different lengths  from 6.8 s
to 16.2 s, along with different levels of power
(207284 W). The characteristics of the sonications
in each treatment are summarized in Table I. An
experienced veterinarian performed careful daily clin-
ical follow-up after each procedure. Complete blood
counts, electrolytes and liver function tests were
performed daily. Follow-up by MRI was performed
at the beginning of each treatment. Three weeks after
the fourth treatment, the dog was operated by an
experienced human liver surgeon. The entire perito-
neal cavity, the liver and adjacent organs were
inspected. The tumour was resected and pathologi-
cally examined.
Results
The procedure
The length of each sonication including the apnoea
and the inter-apnoea ventilation period was almost 2
min. The total length of the anaesthesia was in the
range of 125215 min. No motion artifacts during
apnoea interfered with the image quality. The liver
returned to the same location between sonications.
During sonications the liver was practically motion-
less, and the thermal imaging was adequate. The
range of temperatures achieved in the ablated foci of
each sonication was 60828C. A description of the
characteristics of sonications given in each treatment
is provided in Table I. The dog remained haemody-
namically stable during and after all four treatment
sessions. The dog was fully recovered from
each treatment within 1 h after the termination of
anaesthesia, and resumed eating and normal
behaviour.
Complications
There was one post treatment complication event,
which became evident after the fourth treatment. The
ultrasound beam in its proximal pass zone created a
localized thermal injury to the right costal margin in
the mid-clavicular line. This area of thermal injury
became infected and fistulated to the skin. The lesion
was surgically treated and healed completely.
Blood tests
All blood tests taken during the procedures and the
follow-up, including blood counts, electrolytes, crea-
tinine, amylase, liver function tests and coagulation
profile, were normal, except a moderate (up to four
times the normal levels), transient elevation of liver
transaminases (AST, ALT and GGT), observed dur-
ing the first 3 days after the procedures. Alkaline
phosphatase was also transiently elevated up to three
times the normal limits, during 1 week after the
procedures. Bilirubin remained within normal limits.
Creatine phosphokinase (CPK) was transiently ele-
vated up to two to four times the normal limits after
each session.
Post treatment imaging
Immediate post treatment contrast-enhanced images
showed areas of non-perfused tissue, which matched
the thermal dose areas created during the procedures.
According to the thermal dose mapping, each sonica-
tion created an elliptic focus of high temperature,
2234 mm in length and 3.26.4 mm in diameter,
fully compatible with their expected size. The non-
perfused tissue in the post treatment contrast-en-
hanced imaging perfectly matched the pretreatment
imaging plus the new ablated area of the same session.
The changes in the volume of the tumour during the
experiment and the volume of the non-perfused areas
before and after treatments are shown in Table II. The
volume of the tumour itself grew significantly during
that period. The geometric pattern of the dose
mapping which was created during each treatment
perfectly overlapped the new non-perfused area
(Figures 2 and 3). The anatomical arrangements of
the necrotic areas that were observed in the specimen
were in full accordance with the post treatment
contrast imaging done immediately after the fourth
procedure.
Pathology
The tumour was completely resected 21 days after the
fourth treatment and 118 days after the first treat-
ment. The resected tumor was histopathologically
examined and revealed a well-differentiated hepato-
cellular adenoma, with tumour growth in large
cellular aggregates and sheets and interspersed bun-
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dles of fibrous tissue, some with entrapped haemosi-
derin-laden macrophages. Large zones of necrosis
were found within the tumour (Figure 4). Intracel-
lular details were lost  typical of coagulation necrosis
(Figure 5). Complete destruction of the tumoral
tissue appeared adjacent to major blood vessels of
the tumour, which were included in the treatment
area, indicating that the entire tumoral tissue sur-
rounding these vessels had been completely ablated.
Discussion
Focused ultrasound thermal ablation has been known
for many years [15]. The lack of real-time imaging
control and tissue thermometry has made this tech-
nology very inaccurate. The actual location of the
beam focus could be roughly predicted. Real-time
verification of the result in terms of tissue temperature
and perfusion could not be achieved. A new combined
technology of focused ultrasound with MRI was
presented by Jolesz and Hynynen [14,16,17]. Several
clinical reports were published regarding the ablation
of breast tumours and uterine fibroids [1719]. In the
past, liver tissue and liver tumours have been treated
with FUS, both in animal studies and clinical trials.
These trials proved the ability of FUS to create
irreversible sharply demarcated homogeneous coagu-
lative necrosis. FUS in all these studies was performed
with partial imaging guidance of diagnostic US or
with no imaging at all, without temperature monitor-
ing, and no real-time control or feedback regarding
the deposited thermal dose [2025]. Wu et al.
recently published their experience of ablating pri-
mary liver tumors with ultrasound-guided high in-
tensity focused ultrasound (HIFU) [12]. The added
value of MRI guidance to the process of focused
ultrasound ablation deserves an elaboration. At the
beginning of every MRI-guided FUS treatment, it is
usual practice to verify the accuracy of the system by
applying an experimental diminished power sonica-
tion. Very often the thermometry of the MRI guidance
shows deviation of the foci from their predicted
location, then an adjustment of the system to the
specific parameters of that treatment is performed.
The non-MR-guided HIFU is less accurate, and the
efficacy of the treatment only becomes evident during
the clinical follow-up. For many patients, the authors
[12] used several sessions of transcatheter arterial
chemoembolization, including 1020 ml of iodinized
oil, 24 weeks before HIFU treatment in order to
decrease tumour blood flow and increase the energy
deposition in the target region. Fourteen patients who
had partial treatment in the first session, as was
proved in the follow-up imaging studies, had some
ribs resected to enable an ‘acoustic window’ for
further HIFU treatment. In some patients, the intra-
procedural ultrasound showed increased grey-scale
changes in the treated area. These changes became
less evident and sometimes disappeared within a few
minutes. Obviously these changes are not used as an
integral part of the treatment process. Follow-up
imaging (Doppler ultrasound, CT or MRI studies)
was performed 36 months after the procedure; these
studies could assess the combined late effect of the
different treatment modalities that were used on these
patients. Actually there was no real-time temperature
mapping, nor imaging feedback that could be used
during the treatment in order to change the treatment
parameters and achieve more accurate results.
MRgFUS, on the other hand, allows online monitor-
ing of the energy deposition and temperature changes
of the induced lesion creation [16,26]. The deposited
dose is defined as the tissue volume that has been
exposed to critical ablative temperature during the
sonications (Table I). The critical thermal dose in
terms of tissue temperature and length of exposure
was described by Sapareto and Dewey in 1984 [26].
They arbitrarily chose a reference temperature of
438C to convert all thermal exposures to equivalent
length of time, to determine its prognostic ability. The
Table I. Characteristics of sonications in each treatment.
Number of
sonications
Average*
power
(W)
Average*
duration
(s)
Average*
energy
(J)
Planned
depth
(mm)
Average*
temperature of
sonicated volume
(8C)
Average*
tissue volume
ablated per
sonication (ml)
Treatment no. 1
35 210.1 16.2 3425.3 65.0 66.0 0.7
Treatment no.2
5 207.2 6.8 1330.2 55.0 62.7 0.3
13 251.6 9.1 1982.0 68.0 60.0 0.2
9 284.2 8.2 2335.9 47.0 80.0 0.9
Treatment no.3
50 264.4 9.3 2450.6 58.0 69.7 0.8
Treatment no. 4
39 220.4 8.9 1991.6 47 82.6 0.6
*Average data are per sonication.
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temperature mapping by MRI enabled us to evaluate
the average tissue volume that was ablated per
sonication. We prefer to describe this ability as a
‘closed circle’ ablation, with real-time feedback and
control over the expected results. The ablative ther-
mal energy in FUS is deposited during a few seconds
only (616 s). This relatively rapid and steep gradient
of tissue temperature in comparison to other thermal
ablation modalities is less dependent on the specific
blood perfusion parameters. Sonication, as performed
by the MRgFUS technique, achieves ablation of a
predetermined area of tissue with a precision of
B/1 mm [13]. Our present study shows that a
relatively large number of consecutive sonications
may be performed safely. We have thermally ablated
relatively small volumes of the tumour, while at the
same time the tumour grew further and expanded in
volume (Table II). In the future, to achieve the
complete ablation of such huge tumours, the pace of
treatment should be increased. By overlapping the
sonication areas, by treating multiple layers with
overlap along the long axis of the sonication, taking
into account their spindle shape and the thin
margin of incompletely ablated tissue, larger volumes
of tumoral tissue may be ablated. In all four sessions
of treatment, we used only one (coronal) layer of
sonications. There was no vertical overlap between
sonication foci, along the long axis of the focus. The
spherical nature of liver tumours and the definite need
in the future for complete tumoral ablation, will
dictate the combined ablation of a few such over-
lapping layers, each layer consisting of several hor-
izontally overlapping single sonications. In this study
we achieved complete tissue destruction within each
treated volume, using 26.5% of horizontal overlap
(Figures 4 and 5). The optimal horizontal and vertical
overlap percentage, both between adjacent sonica-
Table II. Volumes of viable and non-perfused tumoral tissue.
Treatment no.
Days from first
treatment
Total
volume of
tumour (ml)
Non-perfused volume
before treatment (ml)
Non-perfused volume after
treatment (ml)
Viable tumoral
tissue (ml)
1 0 735 0 54 681
2 21 937 54 214 723
3 69 949 291 322 627
4 118 1093 199 234 859
Figure 2. Third liver treatment. Blue coloration shows post
treatment accumulated dose mapping.
Figure 3. Before and after the third liver treatment; T1-weighted contrast-enhanced images. The blue area that appears in Figure 2 is viable
on the pretreatment contrast images (left) and non-perfused on the post treatment images (right).
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tions and between coronal layers, is yet to be explored
in further experiments.
To properly achieve a continuity of ablated foci of
sonications, the tissue being treated should be im-
mobile. Mechanical ventilation with intermittent
apnoea periods overcame this problem of the respira-
tory movement of the liver during sonication. The
training of awake patients to hold their breath during
sonications in FUS liver tumours has been described
[24]. These treatments were performed under partial
US guidance only. There was no imaging during the
sonication itself. MR thermometry is motion sensitive
and in our study the MRgFUS requires general
anaesthesia with intermittent apnoea ventilation. Fu-
ture developments in technology may enable
MRgFUS without general anaesthesia. This may
help to shorten the length of treatment, and hence
enable the ablation of larger tumours, like this
hepatocellular adenoma. Effort should be directed at
trying to substantially shorten the treatment. As
observed in previous studies, an intermediate zone
of incomplete tissue destruction is present around the
margins of the necrotic foci. The presence of these
margins of incomplete destruction must be taken into
account when planning the MRgFUS treatment of a
malignant lesion, by including wider margins of
healthy tissue within the ablated area.
When applying MRgFUS to tumoral tissue, it
should be expected that liver tumours may present
different tissue parameters like neovascularity and
parenchymal heterogeneity, which could influence
the MRgFUS efficacy and impose different sonication
parameters. Special attention must be paid to pre-
venting the ultrasound beam from aiming at bony or
calcified tissue, because of the very high rate of energy
absorbance in such tissue. The complication of
fistulating osteomyelitis of the right lower costal
margin could have been prevented or at least diag-
nosed earlier if the higher levels of CPK after the
treatment had been interpreted correctly.
Nevertheless, the present study indicates that
MRgFUS under general anaesthesia may become a
valuable, safe and accurate addendum to the arma-
mentarium of therapeutic techniques for the ablation
of liver lesions. Being a non-invasive procedure, it has
a definitive advantage over all other invasive and
minimally invasive techniques. Further studies are
needed to validate the safety and efficacy of this
technology in the treatment of benign and malignant
liver tumours.
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